MPN-334 Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis (AdvSM): Results From Part 1 of the Phase 2 Apex Trial
Year: 2024
Type: conference-abstract
Authors: Pankit Vachhani, Tsewang Tashi, Gary Schiller, Stephanie Lee, Miguel Piris-Villaespesa, Helena Pomares, Cristina Bulai Livideanu, Jonathan Lambert, Anthony M. Hunter, Tracy I. George, Jay Patel, Daniel J. DeAngelo, Cristina Papayannidis, Khalid Shoumariyeh, Ben Exter, Lei Sun, Jenna Zhang, LouAnn Cable, Amanda Pilla, Hina A. Jolin, Rachael Easton, Marcus Carden, Vinod Pullarkat
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4401876222